A New Approach to an Old Problem
Coronary heart disease (CHD) is the primary force behind the No. 1 killer in the world, claiming more than 7 million lives each year. That’s like taking out New York City’s population in one fell swoop.
The problem remains out of control because our approach to diagnosing and treating the disease hasn’t kept pace. CHD is often not diagnosed until the late stages and, in many cases, too late.
It’s a mission. It’s a movement. It’s One Brave Idea™.
But what if we knew what triggers CHD long before symptoms and fatal events occur? This would unlock the way to improve treatment and work toward preventing CHD. That’s why the American Heart Association, Verily and AstraZeneca have combined forces to fight this epidemic. Through a $75 million investment in a diverse team of scientists, together with the latest technologies and scientific advances, we have set out to find the weapons and strategies to win the fight against coronary heart disease.
It’s a new way of doing things, it’s a mission, it’s One Brave Idea™.
Dr. Calum MacRae, Vice Chair for Scientific Innovation in the Department of Medicine at Brigham and Women’s Hospital in Boston, and his world-class team were selected as the recipients of the One Brave Idea research award.